The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.

ABSTRACT:

Introduction

Real-world data on the needs of patients with psoriasis and patient-perceived benefits of apremilast are limited. We report such data from France.

Methods

The multicenter, observational REALIZE study was conducted in real-life clinical practice in France and enrolled patients with moderate-to-severe plaque psoriasis who had initiated apremilast per French reimbursement criteria in the 4 weeks preceding enrollment (September 2018-June 2020). Physician assessments and patient-reported outcomes (PROs) were collected at enrollment, 6 months, and 12 months. PROs included the Patient Benefit Index for skin diseases (PBI-S), Dermatology Life Quality Index (DLQI), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). The primary outcome was PBI-S ≥ 1

SUBMITTER: Jullien D 

PROVIDER: S-EPMC10196307 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature